Correction: Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance

Affiliations

• ¹ Division of Antitumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai, 201203, China.
• ² International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Chinese Ministry of Education (MOE), Guangzhou City Key Laboratory of Precision Chemistry Drug Development, School of Pharmacy, Jinan University, No. 601 Huangpu Avenue West, Guangzhou, 510632, China.
• ³ School of Pharmacy, Fudan University, 826 Zhangheng Road, Shanghai, 201203, China.
• ⁴ Jiangsu Aosaikang Pharmaceutical Co.Ltd (ASK Pharm), 699 Kejian Road, Nanjing, 211112, China.
• ⁵ University of Chinese Academy of Sciences, 19A Yuquan Road, Beijing, 100049, China.
• ⁶ School of Life Science and Technology, ShanghaiTech University, 393 Middle Huaxia Road, Shanghai, 201210, China.
• ⁷ International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Chinese Ministry of Education (MOE), Guangzhou City Key Laboratory of Precision Chemistry Drug Development, School of Pharmacy, Jinan University, No. 601 Huangpu Avenue West, Guangzhou, 510632, China. dingke@jnu.edu.cn.
• ⁸ Division of Antitumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai, 201203, China. jding@simm.ac.cn.
• ⁹ Division of Antitumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai, 201203, China. hxie@simm.ac.cn.